NASDAQ:BIIBBiogen Stock Price, Forecast & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BIIB shares have decreased by 5.8% and is now trading at $277.12. View which stocks have been most impacted by Coronavirus.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 17 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Biogen.

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings results on Wednesday, April, 22nd. The biotechnology company reported $9.14 earnings per share for the quarter, topping the Zacks' consensus estimate of $7.73 by $1.41. The biotechnology company had revenue of $3.53 billion for the quarter, compared to analysts' expectations of $3.41 billion. Biogen had a return on equity of 49.22% and a net margin of 40.76%. The company's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period last year, the business earned $6.98 EPS. View Biogen's earnings history.

Biogen announced that its board has initiated a share buyback plan on Monday, December 23rd 2019, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company's leadership believes its stock is undervalued.

31 brokerages have issued 1 year price targets for Biogen's shares. Their forecasts range from $228.00 to $410.00. On average, they anticipate Biogen's stock price to reach $309.63 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View analysts' price targets for Biogen.

News coverage about BIIB stock has trended negative this week, InfoTrie reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Biogen earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Biogen.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Celgene (CELG), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Walt Disney (DIS), Celgene (CELG), Micron Technology (MU) and Intel (INTC).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.11%), DNB Asset Management AS (0.09%), State of Alaska Department of Revenue (0.04%), Cullinan Associates Inc. (0.01%), Livforsakringsbolaget Skandia Omsesidigt (0.01%) and Thomasville National Bank (0.01%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin. View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Municipal Employees Retirement System of Michigan, Richard P Slaughter Associates Inc, Triangle Securities Wealth Management, and IBM Retirement Fund. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin. View insider buying and selling activity for Biogen.

BIIB stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Envestnet Asset Management Inc., Cullinan Associates Inc., Patton Fund Management Inc., DNB Asset Management AS, Polianta Ltd, Livforsakringsbolaget Skandia Omsesidigt, and Arden Trust Co. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos. View insider buying and selling activity for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $277.12.

Biogen has a market capitalization of $45.22 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]